Company Profile

Proteus Digital Health Inc (AKA: Proteus Biomedical Inc)
Profile last edited on: 11/13/2023      CAGE: 5YQ08      UEI: V56LELUJDMV5

Business Identifier: Digital products to collect and aggregate various behavioral, physiological and therapeutic metrics
Year Founded
2001
First Award
2011
Latest Award
2013
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2600 Bridge Parkway Suite 101
Redwood City, CA 94065
   (650) 632-4031
   N/A
   www.proteusbiomed.com
Location: Multiple
Congr. District: 15
County: San Mateo

Public Profile

Proteus Digital Health is pioneering a new category of products and services based on ingestion sensing. Called digital medicines, these new pharmaceuticals integrate medicines with ingestible, wearable, mobile and cloud computing. Its core technology—the digital health feedback system—provides a view into an individual’s personal health choices and physiologic response while enabling new information-based business models. Proteus has received a CE mark in Europe and FDA market clearance in the U.S. for its wearable and Ingestible Sensor™ devices. The company's products include digital medicines; Helius, a healthshare solution that keeps families in tune with those who need care; and wearable sensor-based tools. Proteus has a strategic collaboration with Lloydspharmacy. Formerly known as Proteus Biomedical, Inc. the name change to Proteus Digital Health, Inc. in July 2012.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
250-500
Revenue Range
20M-50M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
150-249

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 1 NIH $300,000
Project Title: Wirelessly Observed Therapy to Monitor Treatment of Mycobacterium Tuberculosis
2011 1 NIH $299,551
Project Title: A Novel Edible Sensor System To Characterize Antiretroviral Therapy Adherence

Key People / Management

  Andrew M Thompson -- President, Chief Executive Officer and co-founder

  Joy Berberich -- Vice President, Finance & Business Services

  Ben Costello -- Vice President, Product Development

  Donald Cowling -- Senior Vice President, Commercial Programs

  Lorenzo Dicarlo

  Steve Fieler -- Chief Financial Officer

  Tony Levitan -- Chief Executive Officer

  Molly O'neill -- Chief Commercial Officer

  David O'Reilly -- Chief Product Officer

  George Savage -- Co-Founder, Chief Medical Officer

  Mark J Zdeblick -- Co-Founder, Chief Technology Officer